3상모집 중단 (진행 중)

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

연구 개요

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

스폰서: 협력: 일라이 릴리
적응증: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
중재: Pirtobrutinib, Venetoclax, Rituximab
목표 등록: 600명
시작일: 2021-09-20
완료(예정): 2027-10-01
등록번호: NCT04965493 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.